Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Development and validation of a brief electronic screening test for cognitive impairment in multiple sclerosis (SCI-MS Test).
Meca-Lallana JE, Prieto-González JM, Jimenez-Veiga J, Carreón-Guarnizo E, Jiménez-Martín I, Hernández-Clares R, Sistiaga-Berrondo A, Carles-Dies R, García-Molina E, Cerdán-Sánchez M, Costa-Arpín E, Croitoru I, Castillo-Triviño T, Iniesta-Martinez F, García-Pérez E, Olascoaga-Urtaza J. Meca-Lallana JE, et al. Mult Scler Relat Disord. 2019 Feb;28:50-56. doi: 10.1016/j.msard.2018.12.003. Epub 2018 Dec 3. Mult Scler Relat Disord. 2019. PMID: 30553169
MiRNA Differences Related to Treatment-Resistant Schizophrenia.
Pérez-Rodríguez D, Penedo MA, Rivera-Baltanás T, Peña-Centeno T, Burkhardt S, Fischer A, Prieto-González JM, Olivares JM, López-Fernández H, Agís-Balboa RC. Pérez-Rodríguez D, et al. Among authors: prieto gonzalez jm. Int J Mol Sci. 2023 Jan 18;24(3):1891. doi: 10.3390/ijms24031891. Int J Mol Sci. 2023. PMID: 36768211 Free PMC article.
Protein Plasma Levels of the IGF Signalling System Are Altered in Major Depressive Disorder.
Fernández-Pereira C, Penedo MA, Rivera-Baltanás T, Pérez-Márquez T, Alves-Villar M, Fernández-Martínez R, Veiga C, Salgado-Barreira Á, Prieto-González JM, Ortolano S, Olivares JM, Agís-Balboa RC. Fernández-Pereira C, et al. Among authors: prieto gonzalez jm. Int J Mol Sci. 2023 Oct 17;24(20):15254. doi: 10.3390/ijms242015254. Int J Mol Sci. 2023. PMID: 37894932 Free PMC article.
Plasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients.
Fernández-Pereira C, Penedo MA, Alonso-Núñez A, Rivera-Baltanás T, Viéitez I, Prieto-González JM, Vilariño-Vilariño MI, Olivares JM, Ortolano S, Agís-Balboa RC. Fernández-Pereira C, et al. Among authors: prieto gonzalez jm. Front Pharmacol. 2024 Apr 24;15:1384198. doi: 10.3389/fphar.2024.1384198. eCollection 2024. Front Pharmacol. 2024. PMID: 38720780 Free PMC article.
Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.
Pato Pato A, Costa Arpín E, Rodríguez Regal A, Rodríguez Constenla I, Cimas Hernando I, Muñoz Pousa I, Naya Ríos L, Lorenzo González JR, Amigo Jorrín MC, Prieto González JM. Pato Pato A, et al. Neurologia (Engl Ed). 2021 Jun;36(5):346-352. doi: 10.1016/j.nrleng.2020.02.001. Epub 2020 Feb 16. Neurologia (Engl Ed). 2021. PMID: 34714232 Free article.
25 results